Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Cross-bridge Cycle01:26

Cross-bridge Cycle

123.5K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
123.5K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.5K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.5K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

2.1K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.1K
Chemical Synapses01:26

Chemical Synapses

12.1K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
12.1K
Chemical Synapses01:26

Chemical Synapses

5.2K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
5.2K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

ECAS-Based Neuropsychological Phenotyping in Amyotrophic Lateral Sclerosis: A Retrospective Study Comparing Different Algorithms.

Neurology and therapy·2026
Same author

Correction: Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis.

Molecular neurodegeneration·2026
Same author

Environmental Personal Exposure Clusters to Investigate Multiple Sclerosis and Amyotrophic Lateral Sclerosis Progression.

Studies in health technology and informatics·2026
Same author

Beyond the surface: Exploring differing aspects of wishes to hasten death in patients with amyotrophic lateral sclerosis.

Palliative & supportive care·2026
Same author

"Silent Echoes of the Day: Dream Content Analysis in Amyotrophic Lateral Sclerosis".

Brain and behavior·2026
Same author

King's stages of amyotrophic lateral sclerosis: an 18F-FDG-PET study of brain connectivity.

Brain : a journal of neurology·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Mar 1, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

10.1K

Esclerosis lateral amiotrófica

Michael A van Es1, Orla Hardiman2, Adriano Chio3

  • 1Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, the Netherlands.

Lancet (London, England)
|May 30, 2017
PubMed
Resumen
Este resumen es generado por máquina.

La esclerosis lateral amiotrófica (ELA) implica la pérdida de neuronas motoras y comparte características con la demencia frontotemporal. Comprender la heterogeneidad de la ELA es clave para desarrollar tratamientos efectivos para esta enfermedad neurodegenerativa.

Más Videos Relacionados

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

3.2K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.7K

Videos de Experimentos Relacionados

Last Updated: Mar 1, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

10.1K
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

3.2K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.7K

Área de la Ciencia:

  • La neurociencia
  • La genética
  • Neurología

Sus antecedentes:

  • La esclerosis lateral amiotrófica (ELA) es un trastorno neurodegenerativo progresivo caracterizado por la pérdida de neuronas motoras.
  • La ELA comparte características patobiológicas significativas con la demencia frontotemporal (FTD), y muchos pacientes presentan síntomas superpuestos.
  • La etiología de la ELA es compleja e implica diversos genes y vías fisiopatológicas, lo que pone de relieve la necesidad de abordar su heterogeneidad.

Objetivo del estudio:

  • Proporcionar una visión global de los enfoques clínicos y diagnósticos actuales para la ELA.
  • Resumir los avances científicos recientes en la comprensión de la genética de la ELA y los mecanismos de la enfermedad.
  • Explorar las estrategias terapéuticas emergentes y el papel de los biomarcadores en el tratamiento de la ELA.

Principales métodos:

  • Revisión de los estudios clínicos y los criterios de diagnóstico para la ELA y la ETF.
  • Análisis de la investigación genética que identifica genes y mutaciones clave asociados con la ELA.
  • Examen de varios modelos de enfermedades, incluidos modelos celulares y animales, para la investigación de la ELA.
  • Evaluación de los estudios de descubrimiento y validación de biomarcadores para la ELA.
  • Evaluación de las estrategias terapéuticas preclínicas y clínicas dirigidas a la ELA.

Principales resultados:

  • La heterogeneidad de la ELA, impulsada por la diversidad genética y molecular, presenta un desafío significativo para el desarrollo de tratamientos.
  • Los avances en la investigación genética han identificado numerosos genes contribuyentes, pero una comprensión unificada de su interacción aún está evolucionando.
  • La investigación de biomarcadores es prometedora para mejorar el diagnóstico y el seguimiento de la progresión de la enfermedad.
  • Se están investigando múltiples estrategias terapéuticas, dirigidas a diferentes aspectos de la fisiopatología de la ELA.

Conclusiones:

  • El tratamiento eficaz de la ELA requiere un enfoque personalizado que tenga en cuenta la heterogeneidad subyacente de la enfermedad.
  • La investigación continua en genética, biomarcadores y nuevos objetivos terapéuticos es crucial para avanzar en el cuidado de la ELA.
  • Comprender la superposición entre ELA y FTD puede ofrecer nuevos conocimientos sobre los mecanismos comunes de la enfermedad y las posibilidades de tratamiento.